VentriPace Medical is a UK-based Medtech company pioneering new solutions at the intersection of cardiac rhythm management and patient care.
Our mission is to transform the way transient conduction disturbances are managed — bridging the gap between hospital-based intervention and true recovery.
By combining advanced sensing, remote monitoring, and intelligent design, we aim to give clinicians greater confidence, and patients the freedom to recover without compromise.

In modern cardiology, permanent pacing tools are often used to manage conduction disturbances that, in many cases, prove to be temporary. For patients experiencing transient conduction abnormalities — whether following TAVI, cardiac surgery, or due to reversible causes — this mismatch can result in unnecessary permanent pacemaker implants
In modern cardiology, permanent pacing tools are often used to manage conduction disturbances that, in many cases, prove to be temporary. For patients experiencing transient conduction abnormalities — whether following TAVI, cardiac surgery, or due to reversible causes — this mismatch can result in unnecessary permanent pacemaker implants, extended hospital stays, and increased strain on healthcare resources.
Despite advances in structural interventions and remote care, the approach to short-term rhythm management has remained largely unchanged. Clinical teams are left making difficult decisions with limited information, and patients can find themselves tethered to hospital beds or devices they may not need.
At VentriPace Medical, we believe there’s a better way — one that aligns with how patients recover today, and how cardiac care is evolving for tomorrow.

Across healthcare systems, rising patient volumes, staffing challenges, and procedural backlogs are making every bed count. In this environment, even a short inpatient stay can create a ripple effect — delaying procedures, extending waiting lists, and increasing system-wide costs.
Yet in many cases, patients remain in hospital not because
Across healthcare systems, rising patient volumes, staffing challenges, and procedural backlogs are making every bed count. In this environment, even a short inpatient stay can create a ripple effect — delaying procedures, extending waiting lists, and increasing system-wide costs.
Yet in many cases, patients remain in hospital not because they need intensive care, but because there’s uncertainty — about diagnosis, timing, or the risk of deterioration. In cardiac rhythm management, that uncertainty often leads to overcautious admissions or premature interventions.
At VentriPace Medical, we’re exploring ways to support clinical confidence, streamline pathways, and reduce reliance on hospital resources — all without compromising safety or outcomes.

Minimally invasive procedures like TAVI and day-case interventions are pushing the boundaries of what’s possible in outpatient care. Yet when it comes to rhythm management, we’re still relying on systems built around permanent solutions — even when the problem may be temporary.
As hospital resources tighten and patient expectations evolve,
Minimally invasive procedures like TAVI and day-case interventions are pushing the boundaries of what’s possible in outpatient care. Yet when it comes to rhythm management, we’re still relying on systems built around permanent solutions — even when the problem may be temporary.
As hospital resources tighten and patient expectations evolve, the need for smart, safe, short-term rhythm support has never been more pressing. Clinicians require tools that provide clarity without forcing premature decisions. Patients deserve care that’s responsive, adaptable, and designed to evolve with their condition.
At VentriPace Medical, our work is focused on bridging that gap — empowering clinicians to make confident, data-informed decisions, and enabling patients to move forward without unnecessary constraints.
Will Simpson – Managing Director & Founder
Will is a medical device professional with a strong track record in fundraising, product development, and early-stage company growth. He has successfully raised capital through angel investors, venture funds, and non-dilutive grant funding, and has played a key role in guiding novel medical technologies from concept through to market launch. Will brings both operational leadership and entrepreneurial vision to VentriPace Medical.
Bob Stern - Chairman
Bob is an experienced Chairman with a strong track record in MedTech investment and company growth. He has secured over $100 million in funding and has been involved in seven successful exits, including Reverse Medical, which was acquired by Medtronic via Covidien. Bob brings board-level leadership, investor insight, and commercial acumen to VentriPace Medical.

Sam Dawkins – Clinical Advisor
Sam is a Consultant Cardiologist at the John Radcliffe Hospital in Oxford and an expert in structural heart interventions. He has led and contributed to numerous international clinical trials and has extensive experience with transcatheter valve technologies. Sam brings deep clinical insight and strategic input to the development of VentriPace Medical’s technology.

André Burch – Business Advisor
André is a seasoned MedTech executive with over 30 years of leadership experience in the medical device industry. He previously served as Vice President of Finance at BIOTRONIK Vascular, helping to scale global operations. As Business Advisor to VentriPace Medical, André provides expertise in financial strategy, operations, and commercial execution.
Bee House - Milton Park, Eastern Avenue, Park Drive, Milton, Abingdon, UK